HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Autosomal dominant polycystic kidney disease — Clinical Guidelines

Overview

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development of numerous cysts in the kidneys, leading to progressive renal dysfunction and potential extrarenal manifestations such as polycystic liver disease and intracranial aneurysms. 1

Diagnosis

Genetic Testing: Confirmation through genetic analysis of PKD1 or PKD2 mutations. 1

Imaging Studies: Ultrasound, CT, or MRI to visualize cysts and assess kidney structure. 1

Estimated GFR: Use of formulas like CKD-Epi and aMDRD for monitoring kidney function, though noted to have limitations in accuracy for ADPKD patients. 5

Management

Tolvaptan: Approved for slowing kidney function decline in ADPKD patients at risk of rapid progression. 2

Lifestyle Modifications: Diet, fluid management, physical activity, and pain management strategies recommended. 3

Pain Management: Laparoscopic cyst decortication and marsupialization for symptomatic relief in refractory cases. 6 7

Screening for Intracranial Aneurysms: Considered based on clinical indications such as family history of aneurysm rupture, stroke, or migraine. 4

Special Populations

Pregnancy: Specific considerations and management strategies are part of guideline recommendations but detailed evidence from abstracts is limited. 1

Pediatric Issues: Guidelines include pediatric aspects, emphasizing early diagnosis and management tailored to age-specific needs. 1

Comorbidities: Hyperuricemia and gout are noted comorbidities with higher prevalence in ADPKD patients compared to other chronic renal failure etiologies. Management of hyperuricemia may be necessary. 8

Key Recommendations

Use Tolvaptan for Slowing Kidney Function Decline in appropriate ADPKD patients at risk of rapid progression. (Evidence: Strong 2)

Integrate Patient-Centered Care focusing on lifestyle modifications, psychosocial support, and pain management strategies. (Evidence: Moderate 3)

Consider Screening for Intracranial Aneurysms in ADPKD patients with specific clinical risk factors such as family history of aneurysm rupture. (Evidence: Weak 4)

Monitor Kidney Function with Caution due to limitations of GFR estimation formulas in ADPKD. (Evidence: Moderate 5)

Evaluate and Manage Comorbid Conditions like hyperuricemia and gout, given their higher incidence in ADPKD patients. (Evidence: Moderate 8)

References

1 Torres VE, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB et al.. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney international 2025. link 2 Shoaf SE, Ouyang J, Sergeyeva O, Estilo A, Li H, Leung D. A . Clinical journal of the American Society of Nephrology : CJASN 2020. link 3 Tong A, Tunnicliffe DJ, Lopez-Vargas P, Mallett A, Patel C, Savige J et al.. Identifying and integrating consumer perspectives in clinical practice guidelines on autosomal-dominant polycystic kidney disease. Nephrology (Carlton, Vic.) 2016. link 4 Flahault A, Trystram D, Fouchard M, Knebelmann B, Nataf F, Joly D. Screening for Unruptured Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Survey of 420 Nephrologists. PloS one 2016. link 5 Ruggenenti P, Gaspari F, Cannata A, Carrara F, Cella C, Ferrari S et al.. Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study. PloS one 2012. link 6 McNally ML, Erturk E, Oleyourryk G, Schoeniger L. Laparoscopic cyst decortication using the harmonic scalpel for symptomatic autosomal dominant polycystic kidney disease. Journal of endourology 2001. link 7 Teichman JM, Hulbert JC. Laparoscopic marsupialization of the painful polycystic kidney. The Journal of urology 1995. link 8 Mejías E, Navas J, Lluberes R, Martínez-Maldonado M. Hyperuricemia, gout, and autosomal dominant polycystic kidney disease. The American journal of the medical sciences 1989. link

Autosomal dominant polycystic kidney disease